title: EXCELS study results do not rule out potential cancer risk with omalizumab.
authors.affiliation: Division of Epidemiology II, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md. Electronic address: jie.j.li@fda.hhs.gov.
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.affiliation: Division of Epidemiology II, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
authors.forename: Margie
authors.initials: M
authors.lastname: Goulding
authors.affiliation: Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
authors.forename: Sally
authors.initials: S
authors.lastname: Seymour
authors.affiliation: Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
authors.forename: Peter
authors.initials: P
authors.lastname: Starke
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized